Banque Pictet & Cie SA Trims Holdings in Edwards Lifesciences Corporation $EW

Key Points

• Banque Pictet & Cie SA has reduced its holdings in Edwards Lifesciences Corporation by 25.7%, owning 138,965 shares after selling 48,150 shares in the 2nd quarter.
• Several analysts have raised their price targets for Edwards Lifesciences, with Piper Sandler increasing it from $83.00 to $90.00 and JPMorgan Chase upgrading it from $80.00 to $85.00.
• Insider activity includes sales from VP Daniel J. Lippis and insider Larry L. Wood, reducing their ownership stakes in the company.

Banque Pictet & Cie SA reduced its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 25.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 138,965 shares of the medical research company's stock after selling 48,150 shares during the period. Banque Pictet & Cie SA's holdings in Edwards Lifesciences were worth $10,868,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Quantbot Technologies LP purchased a new position in shares of Edwards Lifesciences during the first quarter worth about $26,000. SouthState Corp acquired a new stake in Edwards Lifesciences during the 1st quarter worth approximately $27,000. Global X Japan Co. Ltd. lifted its position in Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after acquiring an additional 216 shares during the period. Tradewinds Capital Management LLC grew its stake in shares of Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after purchasing an additional 205 shares during the last quarter. Finally, Rossby Financial LCC purchased a new position in shares of Edwards Lifesciences in the 1st quarter valued at approximately $29,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider directly owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.29% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on EW shares. Piper Sandler upped their price target on Edwards Lifesciences from $83.00 to $90.00 and gave the stock an "overweight" rating in a research note on Friday, July 25th. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a research report on Friday, July 25th. Daiwa America upgraded shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 29th. Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. Finally, Royal Bank Of Canada lifted their price objective on Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of "Moderate Buy" and a consensus target price of $86.61.

Edwards Lifesciences Price Performance

EW stock opened at $75.35 on Friday. The stock's 50 day moving average price is $78.50 and its 200 day moving average price is $75.62. The firm has a market cap of $44.24 billion, a P/E ratio of 10.84, a PEG ratio of 3.59 and a beta of 1.07. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. During the same period in the previous year, the firm posted $0.70 earnings per share. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.